Showing 1,881 - 1,900 results of 4,956 for search 'significant ((((((shape decrease) OR (step decrease))) OR (mean decrease))) OR (small decrease))', query time: 0.55s Refine Results
  1. 1881

    Results of comparison experiments. by Wen-Qing Huang (5258126)

    Published 2024
    “…Subsequently, the images are evenly partitioned into small patch blocks, serving as inputs to the enhanced Transformer model. …”
  2. 1882

    Architecture of Swin Transformer Block. by Wen-Qing Huang (5258126)

    Published 2024
    “…Subsequently, the images are evenly partitioned into small patch blocks, serving as inputs to the enhanced Transformer model. …”
  3. 1883

    Disease distribution map of the GZDL-BD. by Wen-Qing Huang (5258126)

    Published 2024
    “…Subsequently, the images are evenly partitioned into small patch blocks, serving as inputs to the enhanced Transformer model. …”
  4. 1884

    Token merging module. by Wen-Qing Huang (5258126)

    Published 2024
    “…Subsequently, the images are evenly partitioned into small patch blocks, serving as inputs to the enhanced Transformer model. …”
  5. 1885

    Comparative results of the ablation experiments. by Wen-Qing Huang (5258126)

    Published 2024
    “…Subsequently, the images are evenly partitioned into small patch blocks, serving as inputs to the enhanced Transformer model. …”
  6. 1886
  7. 1887
  8. 1888
  9. 1889
  10. 1890
  11. 1891

    Data Sheet 1_Remarkable tumor response to Iruplinalkib in a 14-year-old girl with ALK-positive advanced metastatic non–small-cell lung cancer: a case report.pdf by Jiahao Wang (4710915)

    Published 2025
    “…<p>Targeted therapies for anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) generally extend survival and alleviate symptoms. …”
  12. 1892

    Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic N... by Xinhang Gu (22686224)

    Published 2025
    “…Background<p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-based combination therapy modalities for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) are being investigated. …”
  13. 1893
  14. 1894
  15. 1895
  16. 1896
  17. 1897
  18. 1898
  19. 1899
  20. 1900